AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2022
Feb 5, 2022
32883_dirs_2022-02-04_e80addd0-545b-4798-a02b-90a5d18dd760.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-02-02
Reporting Person: Cittadine Andrew (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-02 | Stock Options | $2.80 | A | 85000 | Acquired | 2032-02-01 | Common Stock (85000) | Direct |
| 2022-02-02 | Restricted Stock Units | $0 | A | 65000 | Acquired | Common Stock (65000) | Direct |
Footnotes
F1: Options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
F2: RSUs vest 6/48ths on June 30, 2022 and 3/48ths per quarter thereafter (September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025)